Lorigerlimab

Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART) . Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) [1][2][3].

Product Specifications

CAS Number

[2416595-46-3]

Product Name Alternative

MGD019

UNSPSC

12352203

Target

CTLA-4; PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lorigerlimab.html

Purity

97.5

Solubility

10 mM in DMSO

Smiles

[Lorigerlimab]

Molecular Weight

(166.4 kDa)

References & Citations

[1]Jason J. Luke, et al. Lorigerlimab, a bispecific PD-1xCTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) : A phase 1 expansion (exp) cohort. Journal of Clinical Oncology 2023 41:6_suppl, 155-155. |[2]Berezhnoy A, et al. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1 (9) :100163. |[3]Trojaniello C, Luke JJ, Ascierto PA. Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Front Oncol. 2021 Jun 10;11:670726.